Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label single-arm study of PA3-17 in adults with relapsed/refractory T-lymphoblastic leukemia/lymphoma
CTR20253848Phase 2Active
- Sponsor
- PersonGen Anke Cellular Therapeutics
- Start
- Dec 2025
- Modality
- Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of PA3-17 in Precursor T-cell lymphoblastic leukemia/lymphoma (T-LBL/ALL), early T-cell precursor acute lymphoblastic leukemia (ETP-ALL), sponsored by PersonGen Anke Cellular Therapeutics. Started Dec 2025; status: active.
02
Drugs
PA3-17
03
Conditions
Precursor T-cell lymphoblastic leukemia/lymphoma (T-LBL/ALL)early T-cell precursor acute lymphoblastic leukemia (ETP-ALL)
Beyond the preview
Go deeper on CTR20253848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253848.